MX2011008731A - Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. - Google Patents

Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Info

Publication number
MX2011008731A
MX2011008731A MX2011008731A MX2011008731A MX2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A
Authority
MX
Mexico
Prior art keywords
rtki
eye
delivery
compounds
pharmaceutical composition
Prior art date
Application number
MX2011008731A
Other languages
English (en)
Spanish (es)
Inventor
Bhagwati P Kabra
Malay Ghosh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2011008731A publication Critical patent/MX2011008731A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011008731A 2009-03-03 2010-03-03 Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. MX2011008731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
MX2011008731A true MX2011008731A (es) 2011-09-29

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008731A MX2011008731A (es) 2009-03-03 2010-03-03 Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Country Status (12)

Country Link
US (2) US20100227905A1 (cg-RX-API-DMAC10.html)
EP (1) EP2403335B1 (cg-RX-API-DMAC10.html)
JP (1) JP5583146B2 (cg-RX-API-DMAC10.html)
KR (2) KR20160135372A (cg-RX-API-DMAC10.html)
CN (1) CN102340991B (cg-RX-API-DMAC10.html)
AU (1) AU2010221369B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1012302A2 (cg-RX-API-DMAC10.html)
CA (1) CA2753690A1 (cg-RX-API-DMAC10.html)
ES (1) ES2508290T3 (cg-RX-API-DMAC10.html)
MX (1) MX2011008731A (cg-RX-API-DMAC10.html)
WO (1) WO2010101992A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201105505B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
EP2595603A1 (en) * 2010-07-21 2013-05-29 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2013019640A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
MX2017007873A (es) 2014-12-15 2017-11-06 Univ Johns Hopkins Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
EP4065131B1 (en) * 2019-11-28 2024-09-18 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
EP0842663A4 (en) * 1996-05-07 2003-06-18 Toray Industries OPHTHALMIC PREPARATIONS
KR100976076B1 (ko) * 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
CA2693888A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Also Published As

Publication number Publication date
CN102340991A (zh) 2012-02-01
ES2508290T3 (es) 2014-10-16
JP5583146B2 (ja) 2014-09-03
JP2012519694A (ja) 2012-08-30
AU2010221369A1 (en) 2011-08-25
BRPI1012302A2 (pt) 2015-09-22
WO2010101992A1 (en) 2010-09-10
EP2403335B1 (en) 2014-08-20
CN102340991B (zh) 2014-02-26
US20100227905A1 (en) 2010-09-09
US20130137741A1 (en) 2013-05-30
KR20110130454A (ko) 2011-12-05
EP2403335A1 (en) 2012-01-11
ZA201105505B (en) 2013-10-30
AU2010221369B2 (en) 2014-03-13
KR20160135372A (ko) 2016-11-25
EP2403335A4 (en) 2012-08-29
CA2753690A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
TW200733958A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
MX2021012934A (es) Lipidos de amina ionizables y nanoparticulas lipidicas.
PH12021551279A1 (en) Modified amine lipids
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
UA102681C2 (ru) Тризамещенные 1,2, 4-триазолы как модуляторы никотиновых ацетилхолиновых рецепторов
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
WO2009100441A3 (en) Depot formulations
MY157790A (en) Trazodone composition for once a day administration
PL2081547T3 (pl) Postać galenowa do podawania składników czynnych poprzez śluzówkę
MY147212A (en) Trisubstituted 1,2,4-triazoles
WO2012054500A3 (en) Compositions for drug administration
MX363435B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2007048219A3 (en) Sustained drug release composition
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
WO2008140507A8 (en) Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
MY183471A (en) Formulation for anti-?4?7 antibody
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
IN2013MN02384A (cg-RX-API-DMAC10.html)
MX2010005013A (es) Composiciones intranasales.
WO2007076448A3 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Legal Events

Date Code Title Description
FG Grant or registration